Salvus Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.27M Sell
1,893
-75
-4% -$76.6K 1.27% 24
2026
Q1
$1.81M Buy
1,968
+66
+3% +$66.9K 1.05% 29
2025
Q4
$2.04M Buy
1,902
+67
+4% +$64.1K 1.14% 26
2025
Q3
$1.4M Sell
1,835
-55
-3% -$40.9K 0.78% 35
2025
Q2
$1.47M Buy
1,890
+5
+0.3% +$3.88K 0.86% 34
2025
Q1
$1.56M Buy
1,885
+215
+13% +$179K 0.98% 33
2024
Q4
$1.29M Buy
1,670
+281
+20% +$233K 0.82% 32
2024
Q3
$1.23M Buy
1,389
+45
+3% +$40.5K 0.76% 35
2024
Q2
$1.22M Buy
1,344
+7
+0.5% +$5.6K 0.84% 32
2024
Q1
$1.04M Buy
1,337
+96
+8% +$68.3K 0.71% 38
2023
Q4
$724K Buy
1,241
+25
+2% +$14.6K 0.51% 51
2023
Q3
$653K Buy
1,216
+54
+5% +$27.8K 0.52% 54
2023
Q2
$545K Buy
1,162
+12
+1% +$5.03K 0.42% 65
2023
Q1
$395K Sell
1,150
-15
-1% -$5.06K 0.32% 82
2022
Q4
$426K Hold
1,165
0.39% 64
2022
Q3
$377K Buy
1,165
+25
+2% +$7.92K 0.36% 73
2022
Q2
$370K Sell
1,140
-4
-0.3% -$1.2K 0.33% 76
2022
Q1
$328K Buy
1,144
+55
+5% +$14.2K 0.25% 84
2021
Q4
$301K Buy
1,089
+186
+21% +$47.2K 0.22% 84
2021
Q3
$209K Hold
903
0.17% 99
2021
Q2
$209K Buy
+903
New +$181K 0.18% 94

Other funds holding LLY

Salvus Wealth Management's LLY Position: Q2 2026 in Review

Salvus Wealth Management reduced its Eli Lilly (LLY) stake by 3.8% in Q2 2026, selling an estimated $76.6K and leaving 1,893 shares worth $2.27M. The position accounts for 1.27% of the portfolio, ranked #24.

Salvus Wealth Management first reported a position in LLY in Q2 2021 and has held it in 21 quarters since. 1,393 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Salvus Wealth Management held 1,893 shares of Eli Lilly worth $2.27M as of Q2 2026.
  • Salvus Wealth Management sold 75 Eli Lilly shares in Q2 2026, an estimated $76.6K.
  • Eli Lilly made up 1.27% of Salvus Wealth Management's portfolio in Q2 2026, its #24 holding.
  • Salvus Wealth Management first reported a position in Eli Lilly in Q2 2021 and has held it in 21 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Salvus Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.